Three Types of Racing Upgrades Offered by Hypercar Development

An accomplished entrepreneur based in Anaheim, California, Manny Bojorquez has successfully launched several businesses across different industries. Among Manny Bojorquez’s successful ventures is Hypercar Development, which offers racing upgrades for high-end vehicles like McLarens.

Hypercar Development features three levels of performance upgrades for McLaren race car drivers. The first level, called Phase 1, makes adjustments to a stock McLaren to help it reach an output of 800 horsepower. These upgrades include equipping the car with ultralight wheels made of aerospace aluminum and Michelin Pilot Sport Cup 2 tires. This phase also gives the vehicle a high-flowing full exhaust system and additional heat shielding.

Phase 2 of Hypercar can help drivers break the 1,000-horsepower barrier. To reach that level of speed, technicians upgrade the vehicle’s transmission, driveline, fuel system, and engine blueprint. Phase 2 also includes installation of a patented tri-boost turbocharging system and redesigned aerodynamics to draw maximum performance from the engine enhancements.

Finally, drivers who opt for Hypercar Phase 3 can achieve up to 1,200 horsepower. Also powered by the tri-boost turbocharger, Phase 3 vehicles benefit from additional engine enhancements, further aerodynamic improvements, and suspension upgrades to make them among the fastest vehicles on the track.

How PEA Works to Reduce the Need for Opioids

With an extensive entrepreneurial background, Manny Bojorquez leads companies in areas such as high-end performance vehicles and California legal and medical assistance. Among Manny Bojorquez’s current ventures is peaCURE, which emphasizes a natural supplementation approach through the anti-inflammatory palmitoylethanolamide (PEA).

One of the vital uses of PEA is in helping alleviate the opioid crisis by offering a natural alternative that is safe and effective for managing chronic pain. A major issue for people who use opioids is persistent mast cell activation, which serves to sensitize nociceptors and jumpstart inflammatory processes in the central nervous system.

At the cellular level, this involves sensitization of somatosensory neurons in the spine and microglial cell activation. With opioids highly effective in activating non-neuronal immune cell populations, the end result is that pro-inflammatory and pro-nociceptive processes are promoted, which increases tolerance to the dangerous drugs.

PEA plays a critical role in mediating inflammatory process resolution and helping maintain cellular homeostasis. It down-modulates the activation of microglia and mast cells and reduces the neuropathic pain and inflammation associated with acute stimuli. These analgesic and anti-inflammatory effects target the pathophysiologic mechanisms associated with chronic pain and can thus reduce opioid dependence.